Clinical analysis of the Frailty score in the prognosis of elderly multiple myeloma
10.12025/j.issn.1008-6358.2016.20160734
- VernacularTitle:Frailty评分预测老年多发性骨髓瘤的临床分析
- Author:
Li-Li JI
1
;
Chen CHEN
;
Xue-Jiao ZHANG
;
Wei-Guang WANG
;
Zhi-Xiang CHENG
;
Ling YUAN
;
Zheng WEI
;
Lu-Ya CHENG
;
Jing-Li ZHUANG
;
Zhi-Mei WANG
;
Feng LI
;
Shan-Hua ZOU
;
Peng LIU
Author Information
1. 复旦大学附属中山医院血液科
- Keywords:
multiple myeloma;
Frailty score;
elderly;
adverse event
- From:
Chinese Journal of Clinical Medicine
2016;23(5):586-590
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the Frailty score in the prognosis of elderly multiple myeloma.Methods:Twenty nine multiple myeloma patients aged above 65 year-old admitted from January 1,2015 to February 29,2016 were enrolled in the study.Frailty score assessment was performed and its relation with clinical outcome was analyzed.Results:The 1 3 patients were classified into high risk group (44.8%),5 cases in mediate group (17.2%),and 11 cases in low risk group (37.9%). There were no statistical significance in the aspects of ISS stage (P= 0.281)or chemotherapy intensity (P= 0.475)found among the three groups.More patients (69.2%)in the Frailty high risk group suffered severe hematologic adverse events (≥grade 3),which was significantly higher than low risk group (18.2%,P= 0.014)and mediate risk group (0.0,P= 0.011). The occurrence of adverse reaction in severe non-hematologic group (≥grade 3)(84.6%)was higher than that of low risk group(18.2%,P= 0.001)and that of mediate risk group(20.0%,P= 0.011).There were 69.2% of patients in high risk group had chemotherapy discontinuation,delay or chemotherapy intensity reduction,which was significantly higher than low risk group (9.1%,P= 0.004),and no statistical significance was observed in the mediate risk group (40.0%,P= 0.268).In the terms of therapy efficacy,30.8%,23.1%,and 46.2%patients obtained complete remission or very good remission(CR+VGPR),partial remission (PR),and no remission (NR)in the high risk group,which were significantly lower than low risk group(CR+VGPR 63.6%,PR 36.4%,NR 0.0,P= 0.027).No statistical significance of the efficacy was found between high risk group and mediate risk group (CR+VGPR 40.0%,PR 20.0%,NR 40.0%,P= 0.751).Conclusions:The Frailty score can predict the adverse reaction and treatment efficacy,but with poor prognosis in high risk patients,and its clinical value in prognosis required further research.
